Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Large-Cell, Anaplastic 3Lymphoma 3Immunoblastic Lymphadenopathy 3Esophageal Neoplasms 3Central Nervous System Neoplasms 3Burkitt Lymphoma 3Adenocarcinoma Of Esophagus 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2Precancerous Conditions 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Gliosarcoma 2Glioblastoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Dexamethasone 49Melphalan 29Cyclophosphamide 24Bortezomib 23Filgrastim 18Calcium Dobesilate 18Peripheral Blood Stem Cell Transplantation 16daratumumab 13pomalidomide 10dexamethasone acetate 8Lenalidomide 8ixazomib 6fludarabine phosphate 6dexamethasone 21-phosphate 6venetoclax 5birtamimab 5auricularum 5Whole-Body Irradiation 5Thalidomide 5Mycophenolic Acid 5Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Radiotherapy 4Interferon-alpha 4Etoposide 4Carboplatin 4Busulfan 4sargramostim 3miridesap 3isatuximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Immunoglobulin Light-chain Amyloidosis × Microarray Analysis × Clear all
NCT00520767 2023-12-22

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
35 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡